Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) updated its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 1.800-1.900 for the period, compared to the consensus EPS estimate of 1.600. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on EMBC shares. Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho cut their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Embecta presently has an average rating of “Reduce” and an average price target of $11.00.

Embecta Stock Down 2.0%

Shares of NASDAQ EMBC opened at $3.50 on Friday. The company has a market capitalization of $207.66 million, a PE ratio of 1.84 and a beta of 0.81. The stock’s 50 day moving average price is $3.32 and its 200-day moving average price is $6.67. Embecta has a twelve month low of $2.77 and a twelve month high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.29. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, research analysts expect that Embecta will post 1.62 EPS for the current fiscal year.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Analysts reportedly maintain an average price target of $11.00, substantially above Embecta’s recent trading level, suggesting some analysts see significant recovery potential if the company’s operating and legal issues stabilize. Embecta receives $11 average analyst price target
• Neutral Sentiment: Multiple law firms reminded investors that August 17, 2026 is the deadline to seek appointment as lead plaintiff. The notices concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026; the deadline itself does not establish wrongdoing or determine the outcome of the case. Kaplan Fox Embecta class action deadline notice
• Negative Sentiment: Several firms publicized a pending securities-fraud class action against Embecta and certain executives, alleging violations of federal securities laws and misleading statements about the insulin pen needle business. The repeated investor alerts may reinforce concerns about governance, disclosure quality, and possible financial liabilities. Hagens Berman Embecta investor alert
• Negative Sentiment: The legal pressure follows a sharp deterioration in Embecta’s operating performance: its latest reported quarterly revenue fell 14.4% year over year, while EPS and revenue both missed analyst expectations. That weak backdrop makes the lawsuit allegations more material to investors and helps explain the stock’s decline.

Institutional Investors Weigh In On Embecta

Several hedge funds have recently bought and sold shares of EMBC. Larson Financial Group LLC raised its position in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Embecta during the third quarter worth approximately $94,000. Tower Research Capital LLC TRC boosted its stake in shares of Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares during the period. iSAM Funds UK Ltd purchased a new position in shares of Embecta in the third quarter worth $115,000. Finally, Amundi purchased a new position in shares of Embecta in the fourth quarter valued at about $127,000. 93.83% of the stock is currently owned by institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.